For research use only.
Molecular Weight(MW): 228.24
Resveratrol has a wide spectrum of targets including cyclooxygenases(i.e. COX, IC50=1.1 μM), lipooxygenases（LOX, IC50=2.7 μM）, kinases, sirtuins and other proteins. It has anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects.
Selleck's Resveratrol has been cited by 22 publications
Purity & Quality Control
Choose Selective Autophagy Inhibitors
|Description||Resveratrol has a wide spectrum of targets including cyclooxygenases(i.e. COX, IC50=1.1 μM), lipooxygenases（LOX, IC50=2.7 μM）, kinases, sirtuins and other proteins. It has anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects.|
Resveratrol inhibits the activity of Cyclooxygenase and lipooxygenase, PKCs and p56lck, ERK1, JNK1, p38, IKK β, Src, STAT3, Ribonucleotide Reductase, DNA polymerases α and δ, PKD, PKC α, Quinone reductase 2, and Aromatase with IC50 of from 0.035-60 μM. Resveratrol is also an activator of Adenylyl cyclase and AMPK with EC50 of 0.8 μM and 50 μM, respectively. The roles of Resveratrol as inhibitor or activator enable its effects on decreasing cell inflammatory associated behaviors, growth inhibition and induction of apoptosis in cancer cells, reversal of endothelin-1 stimulated cell responses, inhibition of phorbol ester-induced expression of COX-2, inhibition of DNA synthesis in cell, resistance to menadione-induced cell death, and improvement of cell mitochondrial function and glucose/lipid metabolism.  Resveratrol is also an activator of sirtuins. Resveratrol lowers the Michaelis constant of SIRT1 for both the acetylated substrate and NAD+, and increases cell survival by stimulating SIRT1-dependent deacetylation of p53. In yeast, Resveratrol mimics calorie restriction by stimulating Sir2, increasing DNA stability and extending lifespan.  Resveratrol is effective at protecting isolated rat hearts against ischemia/reperfusion injury via its antioxidant activity, with improved recovery of developed pressure and aortic flow, reduction of malondialdehyde concentrations and reduction of infarct size. 
|In vivo||Resveratrol improves health and survival of mice on a high-calorie diet. Resveratrol (22.4 mg/kg/day) shifts the physiology of middle-aged mice on a high-calorie diet towards that of mice on a standard diet and significantly increases their survival. Resveratrol produces changes associated with longer lifespan, including increased insulin sensitivity, reduced insulin-like growth factor-1 (IGF-I) levels, increased AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor-γcoactivator 1α(PGC-1α) activity, increased mitochondrial number, and improved motor function. Resveratrol opposed the effects of the high-calorie diet in 144 out of 153 significantly altered pathways.  Resveratrol has been shown to inhibit the initiation and growth of tumors in a wide variety of rodent cancer models. Dose of Resveratrol as low as 200 μg/kg daily already shows efficacy in a rat model of colon carcinogenesis. At higher dose of 40 mg/kg, Resveratrol increases the survival of mice with subcutaneous neuroblastomas from 0% to 70%. Resveratrol inhibits vascularization in the corneal micropocket assay in mice at a dose of only 48 μg/kg when administered daily.  Resveratrol shows beneficial effects on heart disease. Resveratrol blocks the increase in platelet aggregation induced by a hypercholesterolaemic diet. Resveratrol increase expression of both endothelial and inducible nitric oxide synthase. In stroke-prone, spontaneously hypertensive rats, resveratrol significantly reduces markers of oxidative stress such as glycated albumin in serum, and 8-hydroxyguanos-ine in urine. Providing Resveratrol in drinking water for 15 days (1 mg/kg) is sufficient to improve the recovery in function and coronary flow of isolated hearts.  Resveratrol displays anti-inflammatory activity in vivo. Resveratrol significantly reduces both acute and chronic chemically induced oedema, lipopolysaccharide-induced airway inflammation and osteoarthritis, and helps to prevent allograft rejection. Intravenously administered Resveratrol decreases inflammation induced by ischaemia/reperfusion, oxidants generated by hypoxanthine/xanthine oxidase (HX/XO) or platelet-activating factor, but not leukotriene B4 in rats.  Resveratrol shows beneficial effects on stroke and brain damage. Resveratrol administered intravenously significantly decreased ischaemic volume and brain water content at the extremely low doses of 100 ng/kg and 1 μg/kg after middle cerebral artery occlusion in rats. |
-  Pirola L, et al. IUBMB Life, 2008, 60(5), 323-332.
-  Howitz KT, et al. Nature, 2003, 425(6954), 191-196.
-  Baur JA, et al. Nat Rev Drug Discov, 2006, 5(6), 493-506.
-  Baur JA, et al. Nature, 2006, 444(7117), 337-342.
-  Wang YJ, et al. Zhonghua Yi Xue Za Zhi, 2003, 83(7), 534-536.
-  Joe AK, et al. Clin Cancer Res, 2002, 8(3), 893-903.
-  Lee MH, et al. Cancer Res, 2009, 69(18), 7449-7458.
-  Yun Wang, et al. Toxicol Sci. 2006, 92 (1): 71-77.
-  Calamini B, et al. Biochem J. 2010 Jul 15;429(2):273-82.
|In vitro||DMSO||45 mg/mL warmed (197.16 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03743636||Recruiting||Drug: Nicotinamide riboside|Drug: Resveratrol|Other: Placebo||Peripheral Artery Disease||Northwestern University|American Heart Association||October 1 2018||Phase 3|
|NCT03253913||Recruiting||Drug: Sirolimus|Drug: Resveratrol||Lymphangioleiomyomatosis||University of Cincinnati|National Heart Lung and Blood Institute (NHLBI)||March 31 2018||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.